论文部分内容阅读
[目的]探讨脑胶质瘤术后三维适形放疗联合替莫唑胺临床疗效。[方法]回顾性分析了84例脑胶质瘤患者,放化疗联合组44例,单纯三维适形放疗组40例,放疗剂量均为60Gy/30F,放化疗联合组口服替莫唑胺。[结果]放化疗联合组和单纯放疗组的中位生存时间(MST)分别为27个月和17个月,中位无进展生存时间(m PFS)分别为16个月和13个月,P值分别为0.04和0.13。放化疗联合组1、3年生存率分别为58.57%和23.65%,单纯放疗组1、3年生存率分别为50.45%和19.54%,放化疗联合组的1年、3年生存率均优于单纯放疗组,两组1年生存率差异有统计学意义(P=0.03)。[结论]放化疗联合较单纯三维适形放疗能提高脑胶质瘤术后患者总体生存时间及无进展生存时间。
[Objective] To investigate the clinical efficacy of three-dimensional conformal radiotherapy combined with temozolomide in patients with glioma after operation. [Methods] 84 patients with glioma were retrospectively analyzed. Forty-four radiotherapy and chemotherapy combined radiotherapy and chemotherapy groups and 40 pure radiotherapy and three radiotherapy conformal radiotherapy groups all received 60 Gy and 30 F radiotherapy. The combination chemotherapy and chemotherapy group received temozolomide. [Results] The median survival time (MST) of radiotherapy and chemotherapy combination group and radiotherapy alone group were 27 months and 17 months, respectively, and the median progression-free survival time (m PFS) was 16 months and 13 months, P The values were 0.04 and 0.13 respectively. The 1-year and 3-year survival rates of radiotherapy and chemotherapy group were 58.57% and 23.65% respectively. The 1- and 3-year survival rates of radiotherapy and chemotherapy group were 50.45% and 19.54% respectively. The 1-year and 3-year survival rates of radiotherapy and chemotherapy group were better than those of radiotherapy and chemotherapy group Radiotherapy alone group, two-year survival rate difference was statistically significant (P = 0.03). [Conclusion] Radiotherapy combined with simple three-dimensional conformal radiotherapy can improve the overall survival time and progression-free survival time of glioma patients.